Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel

Manoj Chawla · Sunil M. Jain · Jothydev Kesavadev · Brij M. Makkar · Vijay Viswanathan · Mangesh Tiwaskar · Aravind R. Sosale · Vijay Negalur · Kirtikumar D. Modi · Mukulesh Gupta · Surinder Kumar · Santosh Ramakrishnan · Nilakshi Deka · Nirmalya Roy

Received: September 22, 2020 / Accepted: November 26, 2020 / Published online: December 12, 2020 © The Author(s) 2020

ABSTRACT

The ongoing global pandemic of the coronavirus disease 2019 (COVID-19) has placed a severe strain on the management of chronic conditions like diabetes. Optimal glycemic control is always important, but more so in the existing environment of COVID-19. In this context, timely insulinization to achieve optimal glycemic control assumes major significance. However, given the challenges associated with the pandemic like restrictions of movement and access to healthcare resources, a simple and easy way to initiate and optimize insulin therapy in people with uncontrolled diabetes is required. With this premise, a group of clinical experts comprising diabetologists and endocrinologists from India discussed the challenges and potential solutions for insulin initiation, titration, and optimization in type 2 diabetes mellitus (T2DM) during the COVID-19 pandemic and how basal insulin can be a good

M. Chawla (✉) Lina Diabetes Care and Mumbai Diabetes Research Centre, Mumbai, Maharashtra, India e-mail: linadiabetes@gmail.com
S. M. Jain TOTAL Diabetes and Hormone Institute, Indore, Madhya Pradesh, India
J. Kesavadev Department of Diabetes, Jothydev’s Diabetes Research Centre, Trivandrum, Kerala, India
B. M. Makkar Dr. Makkar’s Diabetes and Obesity Centre, New Delhi, India
V. Viswanathan M.V. Centre for Diabetes, Chennai, India
M. Tiwaskar Shilpa Medical Research Centre, Mumbai, India
A. R. Sosale Diacon Hospital (Diabetes Care and Research Centre), Bangalore, India
V. Negalur Dr. Negalur’s Diabetes and Thyroid Specialities Center, Thane, India
K. D. Modi CARE Hospitals, Hyderabad, India
M. Gupta Udyaan Health Care, Lucknow, India
S. Kumar Department of Endocrinology, Sir Ganga Ram Hospital, New Delhi, India
S. Ramakrishnan Magna Centers for Obesity, Diabetes and Endocrinology, Hyderabad, India
N. Deka Apollo Hospitals, Guwahati, Assam, India
N. Roy KPC Medical College and Hospital, Kolkata, India
option in this situation owing to its unique set of advantages like lower risk of hypoglycemia, ease of training, need for less monitoring, better adherence, flexibility of using oral antidiabetic drugs, and improved quality of life compared to other insulin regimens. The panel agreed that the existing challenges should not be a reason to delay insulin initiation in people with uncontrolled T2DM and provided recommendations, which included potential solutions for initiating insulin in the absence or restriction of in-person consultations; the dose of insulin at initiation; the type of insulin preferred for simplified regimen and best practices for optimal titration to achieve glycemic targets during the pandemic. Practical and easily implementable tips for patients and involvement of stakeholders (caregivers and healthcare providers) to facilitate insulin acceptance were also outlined by the expert panel. Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM.

**Keywords:** Basal insulin analogues; COVID-19; Diabetes; Insulin degludec; Insulin detemir; Insulin glargine 100 U/mL; Insulin glargine 300 U/mL; Insulin initiation during pandemic; Titration

**A group of clinical experts comprising diabetologists and endocrinologists from India discussed the challenges and potential solutions for insulin initiation, titration, and optimization in type 2 diabetes mellitus (T2DM) during the COVID-19 pandemic and how basal insulin can be a good option in this situation owing to its unique set of advantages.**

**Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM.**

**DIGITAL FEATURES**

This article is published with digital features to facilitate understanding of the article. You can access the digital features on the article’s associated Figshare page. To view digital features for this article go to [https://doi.org/10.6084/m9.figshare.13227848](https://doi.org/10.6084/m9.figshare.13227848).

**INTRODUCTION**

The emergence and rapid spread of the coronavirus disease 2019 (COVID-19) has disrupted healthcare delivery systems across the world. The condition, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late November 2019 and has now assumed pandemic proportions on a global scale [1]. Statistics from the World Health Organization as of August 20, 2020 show that over 21 million people worldwide have been affected with COVID-19 and that over 735,000 people have died with the disease. Data indicates higher mortality risk in people with COVID-19 who have co-morbidities such as diabetes [2].
The data from the pandemic is still evolving, but all evidence suggests that people with co-morbidities such as diabetes, cardiovascular disease, and hypertension are at a heightened risk of experiencing adverse outcomes due to COVID-19 [2].

Studies have shown that people with uncontrolled type 2 diabetes mellitus (T2DM) are at increased risk of severity of complications and mortality due to COVID-19 [3]. A predictive analysis based on pre-pandemic glycemic status in India has demonstrated that glycemic control and diabetes-related complications are likely to worsen with increased duration of lockdown. This may further increase the load on the already stretched healthcare system [4].

Therefore, achieving and maintaining adequate glycemic control during and following the pandemic situation is of utmost importance. Continuing to follow lifestyle modifications needs to be stressed upon by the clinicians during and after the pandemic. Despite its efficacy in achieving glycemic control, the initiation of insulin therapy is often delayed in people with T2DM in India [5]. It is anticipated that delaying insulin initiation is even more common during the COVID-19 pandemic because of the presence of overarching concerns during these times which include [6]:

- Restricted movement
- Reduced access to healthcare resources including medications and glucose test strips
- Missed follow-ups including laboratory tests and visits to healthcare providers
- Restricted time for interaction leading to lack of counselling and training
- Challenges with remote monitoring of blood glucose levels
- Lack of adequate troubleshooting including correction of injection technique and proper use of insulin devices

In view of these unprecedented challenges, a panel of experts comprising diabetologists and endocrinologists from India developed an opinion paper on the need for insulin initiation during and following the COVID-19 pandemic. The brief practical recommendations authored by this group are elucidated in this paper. The expert panel recommends that clinicians follow local government guidelines for management of T2DM including the protocol for insulin initiation during and after the COVID-19 pandemic.

**METHODS**

The RAND/UCLA Appropriateness Method (RAM) was used to arrive at an agreement on various practical issues of insulinization during the COVID-19 pandemic. Developed at the Research and Development (RAND) Corporation/University of California Los Angeles (UCLA) in the 1980s, RAM combines available scientific evidence with collective judgement of experts. The RAM technique obtains agreement from an expert group through rating appropriateness of well-defined clinical situations, on the basis of the appropriateness scale. Agreement is rated as “appropriate”, “uncertain”, or “inappropriate” according to the situation being discussed [7]. On the basis of this technique, a questionnaire was developed to seek clinical insights from the expert panel on initiation, titration, and optimization of basal insulin analogue in times of the COVID-19 pandemic. The questionnaire was circulated prior to a virtual meeting and experts were requested to rate the responses as “appropriate”, “uncertain”, or “inappropriate”. Further, the experts discussed the responses to the questionnaire and provided their inputs during the virtual meeting. The points on which the experts reached agreement and considered the advantage of basal insulin analogue over other insulin regimens during these challenging times are listed here. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**REVIEW RESULTS**

**Challenges and Potential Solutions for Insulin Initiation During the COVID-19 Pandemic**

Delay in initiating insulin therapy has been a major challenge in real-world clinical practice.
Timely initiation of insulin can help mitigate unwanted complications and should be adopted for treating uncontrolled T2DM in the pandemic. In fact, a recent opinion paper by Hirsch and Gaudiani recommends earlier initiation of basal insulin therapy in uncontrolled T2DM. The authors argue that the American Diabetes Association (ADA) 2020 guidelines for diabetes treatment offer little “guidance regarding how treatment might differ based on how much a patient’s hemoglobin A1c (HbA1c) is above the treatment target after metformin is started.” They advocate the use of basal insulin after metformin as a second-line therapy if HbA1c ≥ 9.0% [8].

The expert panel discussed and debated three key questions surrounding insulin initiation during the ongoing COVID-19 pandemic:

1. What are the main challenges related to insulin initiation at present and anticipated in the months ahead?
2. What are the solutions to address these challenges?
3. What are the tips for insulin initiation for primary care physicians and specialists in these times?

The summary of the expert opinion put forth by the panel for these questions is elucidated in Table 1 and Fig. 1.

Table 1  Expert opinion on insulin initiation

| Challenges in initiating insulin |
|----------------------------------|
| Restricted movement means people with T2DM are unable to routinely visit clinics for follow-up care |
| Inability to demonstrate proper injection technique, importance of injection site rotation, and inherent reluctance of people and providers are other barriers for insulin initiation during these times |
| Lack of prompt monitoring of blood glucose is also another factor in the delay of insulin initiation even though tight glycemic control is a must during the pandemic |

| Solutions for initiating insulin |
|----------------------------------|
| Faced with these challenges, providers must strive to offer insulin in a timely manner to patients who remain uncontrolled and definitely to those whose HbA1c levels are > 9.0% regardless of pre-pandemic oral antidiabetic agent-focused care. In resource-restricted settings, where HbA1c may not be available routinely, it would be advisable to initiate insulin in the presence of persistent, uncontrolled fasting and postprandial blood glucose readings. |
| Teleconsultations can be an alternative where face-to-face visits are challenging |
| Video demonstrations of proper injection technique, site rotation, and counselling can help mitigate concerns from the person’s end and smooth out the insulinization journey |
| Local pharmacists can also play an important role during the pandemic as they would be able to help demonstrate injection techniques. Wherever available, it is advisable to co-opt pharmacists for helping support insulin initiation during the pandemic. |

| Tips to initiate insulin |
|--------------------------|
| Primary care physicians and specialists should prefer a safe and convenient insulin regimen, which requires less monitoring during the COVID-19 pandemic |
| It would also be prudent to initiate insulin using disposable pens to avoid the need for changing cartridges and needles. This will help reinforce the simplicity and ease of insulin therapy during the pandemic as changing of cartridges and needles for a reusable pen may be confusing for beginners. |
Which Insulin is Recommended for Simplicity and Ease of Use at Initiation During the COVID-19 Pandemic?

Complex regimens, need for multiple injections, and side effects can hamper the person’s involvement and trust in insulin therapy. A simple and practical therapeutic approach helps empower the person, provides the context for targeting the goals in the management of diabetes mellitus, and boosts the confidence of the person [9]. This holds true in the current pandemic scenario as well.

The 2020 American Diabetes Association Standards of Care stress upon the fact that a basal insulin analogue is the most convenient insulin to initiate in T2DM [10]. A further advantage with basal insulin analogues like glargine 100 U/mL (Gla-100), detemir, glargine 300 U/mL (Gla-300), and degludec (IDeg) is that they involve only one injection per day and do not require adherence to inflexible meal patterns or quantity and composition of the diet [9]. It is also pertinent to note that newer second-generation basal insulin analogues like Gla-300 and IDeg have lower glycemic variability, greater flexibility in dosing, and a sustained glucose-lowering effect with lesser risk of hypoglycemia [11].

The expert panel discussed and debated three key questions surrounding the type of insulin to be used at initiation during the ongoing COVID-19 pandemic:

1. Does basal insulin offer advantages for initiation during the pandemic?
2. What dose should be used to initiate basal insulin and what is the preferred channel?
3. When should the first follow-up be requested? What is the preferred channel?

The expert opinion put forth by the panel for these questions is summarized in Table 2 and Fig. 2.

What Are the Recommendations for Simple and Easy Self-monitoring of Blood Glucose and Insulin Titration During the COVID-19 Pandemic?

Self-monitoring of blood glucose (SMBG) constitutes one of the key tools in T2DM management in general and in insulin therapy in particular. This is because, once initiated, non-
optimally titrated insulin leads to treatment dissatisfaction, discontinuation, and suboptimal glycemic control [11].

Safer and easier titration is facilitated by basal insulin compared with other insulin regimens, which works well with different titration algorithms [11]. The first head-to-head randomized controlled trial between the two second-generation basal insulins, Gla-300 and IDeg-100, in insulin-naïve people with T2DM has indicated lower risk of hypoglycemia during the titration period (initial 12 weeks) with Gla-300 [12].

Further, basal insulin analogues can effectively address glycemic variability by controlling the peaks and troughs of glucose levels. The peaks are addressed by targeting the fasting glucose which in turn minimizes postprandial excursions [13]. The troughs are addressed as there is lesser risk of hypoglycemia with basal insulin analogues as compared with Neutral Protamine Hagedorn (NPH) insulin and premix or co-formulations [14–16].

Individual preference and convenience are important parameters in initiating insulin during the pandemic. In this context, it must be noted that basal insulin analogues offer more flexible options than premix or co-formulations and are associated with increased treatment persistence and adherence [17, 18]. Research has also suggested that persons receiving once-daily dosing had approximately 44% more adherent days compared with those receiving twice-daily dosing [19]. The once-daily dosing offered by basal insulin analogues is also an attractive option for minimizing the risk of exposure to COVID-19 for healthcare providers.

Table 2  Expert opinion on type of insulin to be used at initiation

Basal insulin analogues are the simplest and most convenient option to initiate insulin therapy in persons with T2DM during the ongoing pandemic. It is also easier to train people with diabetes using basal insulin analogues at initiation.

It would be preferable to initiate persons on basal insulin during in-person consultations; however, remote initiation may be favored depending on the mutual agreement between the person and the provider. In case of remote initiation, video consultations to ease the person into the insulin journey are recommended.

The starting dose of basal insulin analogues is 10 units/day or 0.1–0.2 U/kg/day. 10 units/day is easier to remember for physicians in case remembering calculations in challenging.

Follow-up is recommended within 2 weeks of insulin initiation. In-person follow-up is preferred, but remote follow-up via digital media is also feasible depending on the local situation with regards to movement during the pandemic.

Fig. 2  Type of insulin at initiation
and allied staff as has been pointed out by a recent study [20].

The expert panel discussed and debated the following key questions on SMBG and titration options during the ongoing COVID-19 pandemic:

1. When should one start the conversation about titration?
2. What is the minimum frequency of monitoring/SMBG?
3. When should one start titration and what is the preferred channel?
4. What is the preferred default titration algorithm?
5. How long is the average “active” titration phase?
6. What is the parameter to be monitored for titration?

7. What are the points in the insulin journey where in-person consultation is important?
8. What is the minimum follow-up frequency during the active titration phase?
9. What are the profiles for patient-led titration?
10. What is the maximum dose up to which basal insulin should be titrated?
11. What changes should be recommended for the maintenance phase (post “active” titration) for monitoring, in-person visit requirement, etc.?
12. What are the important points emphasized post “active” titration?

The expert opinion put forth by the panel for these questions is summarized in Table 3 and Fig. 3.

**Table 3** Expert opinion on SMBG and titration phase

SMBG should be performed at least twice a week. During the initial titration period, daily SMBG may be required, but this is at the physicians’ discretion.

The titration conversation should be started on the day of insulin initiation.

A simple and easy titration algorithm for basal insulin analogues during the COVID-19 pandemic is a simple + 2U/week or - 2U/week until the fasting glucose target of < 120 mg/dl is achieved. It is also easier to train people with diabetes using basal insulin analogues to adjust the doses.

Basal insulin analogues have been successfully tried in different titration algorithms (like titration daily, once in 3 days, weekly, etc.) which can also be used depending on the profile of the person with diabetes.

Titration should be initiated as soon as possible, preferably within 2 weeks of insulin initiation. “Active” titration period is defined as a period of up to 12 weeks after insulin initiation when there is frequent adjustment of doses.

Titration should be based on fasting blood glucose readings.

In-person follow-up should be encouraged once in 3 months, although more frequent follow-ups will be needed in case of frequent hypoglycemic episodes or persistent hyperglycemia.

Basal insulin analogues can be titrated up to a maximum dose of 0.5 U/kg/day. In India, basal insulin once initiated is not titrated adequately. Previous literature suggests basal insulin is titrated to only 18 units. Efforts should be made to up-titrate basal insulin once initiated to at least 40 units/day if not 0.5 U/kg/day without compromising on safety. Up-titration is less challenging with second-generation basal insulin analogues.

Person-led titration can be encouraged in motivated and educated persons who can understand and implement the insulin injection techniques and titration algorithms in a safe and easy manner.

Following a period of active titration, persons should be encouraged to monitor glycemic parameters regularly—at least once in 3 months. Physicians should periodically review injection techniques, site rotation, and opt for down-titration if required.
CONCLUSION

Routine care of diabetes has been adversely impacted during the COVID-19 pandemic in India. Increased stress levels, reduced physical activity, restrictions of movement, and limited access to healthcare associated with the pandemic could contribute to worsening outcomes in people with T2DM. The existing challenges should not be a reason to delay insulin initiation in people with uncontrolled T2DM. To overcome these challenges, simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic. The expert panel opined that basal insulin analogues may be preferred during and following the pandemic in order to achieve glycemic control owing to the unique set of advantages such as lower risk of hypoglycemia, ease of training, need for less monitoring, better adherence, flexibility of using oral antidiabetic drugs, and improved quality of life compared to other insulin regimens.

ACKNOWLEDGEMENTS

All authors had full access to the articles reviewed in this manuscript, have read and reviewed the final draft of this manuscript and take complete responsibility for the integrity and accuracy of this manuscript. Before submission to the journal, Sanofi was given the opportunity to review the manuscript. However, the authors remain responsible for all content and editorial decisions. The content published herein solely represents the views and opinions of the authors and does not necessarily represent the views or opinion of Sanofi and/or its affiliates. The details published herein are intended for informational, educational, academic and/or research purposes and are not intended to substitute for professional medical advice, diagnosis or treatment. This expert opinion article is not intended to supplement, or supersede, the most up to date guidance related to the COVID-19 outbreak from international and local health authorities. No product mentioned in this expert opinion article is indicated for the prevention or treatment of COVID-19.

Funding. This expert opinion initiative is supported by Sanofi India. Medical writing and the journal’s rapid service fee were paid for by Sanofi India. The authors received no honoraria from Sanofi directly or indirectly related to the development of this publication.

Authorship. All named authors meet the International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Medical Writing and Editorial Assistance.** We would like to thank Dr Rajshri Malabadi from BioQuest Solutions Pvt. Ltd, Bangalore, for providing medical writing assistance and editorial support in the preparation of this manuscript, which was paid for by Sanofi, India.

**Disclosures.** Manoj Chawla, Sunil M Jain, Jothydev Kesavadev, Brij M Makkar, Vijay Viswanathan, Mangesh Tiwaskar, Aravind R Sosale, Vijay Negalur, Kirtikumar D Modi, Mukulesh Gupta, Surinder Kumar, Santosh Ramakrishnan, Nilakshi Deka and Nirmalya Roy have nothing to disclose.

**Compliance with Ethical Guidance.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**Data Availability.** Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

**REFERENCES**

1. Coronavirus disease 2019 (COVID-19) Situation Report-94. World Health Organization. 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200423-sitrep-94-covid-19.pdf?sfvrsn=b8304bf0_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200423-sitrep-94-covid-19.pdf?sfvrsn=b8304bf0_4). Accessed 5 Oct 2020.

2. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546–50.

3. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.

4. Ghosal S, Sinha B, Majumder M, et al. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: a simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020;14:319–23.

5. Kalra S, Bajaj S, Sharma SK, et al. A practitioner’s toolkit for insulin motivation in adults with type 1 and type 2 diabetes mellitus: evidence-based recommendations from an international expert panel. Diabetes Ther. 2020;11:S58–606.

6. Managing diabetes during the COVID-19 pandemic. [https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/](https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/). Accessed 6 July 2020.

7. The RAND/UCLA appropriateness method user’s manual. [https://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf](https://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf). Accessed 6 July 2020.

8. Hirsch IB, Gaudiani LM. Using insulin to treat poorly controlled type 2 diabetes in 2020. JAMA. 2020. [https://doi.org/10.1001/jama.2020.1303](https://doi.org/10.1001/jama.2020.1303).

9. Ghosh S, Ghosh R. Glargine-300: an updated literature review on randomized controlled trials and real-world studies. World J Diabetes. 2020;11:100–14.

10. American Diabetes Association. Standards of medical care in diabetes—2020. [https://care.diabetesjournals.org/content/43/Supplement_1/S98.full-text.pdf](https://care.diabetesjournals.org/content/43/Supplement_1/S98.full-text.pdf). Accessed 6 July 2020.
11. Jain SM, Seshadri K, Unnikrishnan AG, et al. Best practices and tools for titrating basal insulins: expert opinion from an Indian panel via the modified Delphi consensus method. Diabetes Ther. 2020;11:621–32.

12. Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–54. https://doi.org/10.2337/dc18-0559.

13. Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocrinol Metab. 2016;20:408–11.

14. Hanefeld M, Koehler C, Hoffmann C, et al. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med. 2010;27:175–80.

15. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–9. https://doi.org/10.2337/diabcare.28.2.254.

16. Kumar S, Jang HC, Demirag NG, et al. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with type 2 diabetes: a randomized, treat-to-target study. Diabet Med. 2017;34:180–8. https://doi.org/10.1111/dme.13125.

17. Kumar A, Franek E, Wise J, et al. Efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (U100) for 52 weeks in insulin-naïve patients with type 2 diabetes: a randomized controlled trial. PLoS One. 2016;11:e0163350.

18. Baser O, Tangirala K, Wei W, et al. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res. 2013;5:497–505.

19. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-33.

20. Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: a narrative review. Diabetes Res Clin Pract. 2020;165:108266.